Company Name Euthymics Bioscience
Mailing Address 43 Thorndike St. Cambridge, MA 02141
Company Description Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment.
Proceeds Purposes This is an add on to the existing series A. According to Euthymics officials, the new funds will be used to move forward preclinical development of its second product candidate EB-1020, a non-stimulant for adult ADHD (attention deficit/hyperactivity disorder).